Investor Presentation

November 2024

TRANSFORMING THE VALUE OF HOMECARE



veanna

Disclaimers and Forward-Looking Statements

This investor presentation (this "presentation") and any oral statements made in connection with this presentation are for information purposes only and do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other securities of Aveanna Healthcare Holdings Inc. (including its consolidated subsidiaries, "Aveanna," the "Company," "we," "us" or "our"). The information contained herein does not purport to be all inclusive. The data contained herein has been derived from various internal and external sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of such information. Any data on past performance contained herein is not an indication as to future performance. Except as required by applicable law, Aveanna assumes no obligation to update the information. Nothing herein shall be deemed to constitute investment, legal, tax, financial, accounting or other advice. This presentation is not intended for distribution to, or use by, any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. No representation or warranty (whether express or implied) has been made by Aveanna with respect to the matters set forth in this presentation.

Cautionary Note Regarding Forward-Looking Statements

Certain matters discussed in this presentation constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business strategy, expected financial and operational results, and any other future events may constitute forward-looking statements. Forward-looking statements generally can be identified by the use of terminology such as "believe," "expect," "anticipate," "design," "would," "could," "proiect," "project," "project," "project," "project," "project," "project," "project," "project," "project," "anticipate," "design," would," "could," "could," "could," "section and "project," "project," "project," "project," "project," "anticipate," anticipate," "design," would," "could," "could," "could," "section and "project," them or similar expressions. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. Forward-looking statements involve a number of risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, such as our ability to successfully execute our growth strategy. including through organic growth and the completion of acquisitions, effective integration of the companies we acquire, unexpected costs of acquisitions and dispositions, the possibility that expected cost synergies may not materialize as expected, the failure of Aveanna or the companies we acquire to perform as expected, estimation inaccuracies in revenue recognition, our ability to drive margin leverage through lower costs, unexpected increases in SG&A and other expenses, changes in reimbursement, changes in government regulations, changes in Aveanna's relationships with referral sources, increased competition for Aveanna's services or wage inflation, the failure to retain or attract employees. changes in the interpretation of government regulations or discretionary determinations made by government officials, uncertainties regarding the outcome of rate discussions with managed care organizations and our ability to effectively collect our cash from these organizations, changes in the case-mix of our patients, as well as the pavor mix and payment methodologies, legal proceedings, claims or governmental inquiries, our ability to effectively collect and submit data required under Electronic Visit Verification regulations, our ability to comply with the terms and conditions of the CMS Review Choice Demonstration program, our ability to effectively implement and transition to new electronic medical record systems or billing and collection systems, a failure to maintain the security and functionality of our information systems or to defend against or otherwise prevent a cybersecurity attack or breach, changes in tax rates, our substantial indebtedness, the impact of adverse weather, and other risks set forth under the heading "Risk Factors" in Aveanna's Annual Report on Form 10-K for its 2023 fiscal year filed with the Securities and Exchange Commission (the "SEC") on March 14, 2024, which is available at www.sec.gov, as well as under similar headings in Aveanna's subsequently filed Quarterly Reports on Form 10-Q and other filings with the SEC. In addition, these forward-looking statements necessarily depend upon assumptions, estimates and dates that may prove to be incorrect or imprecise. Accordingly, forward-looking statements included in this presentation do not purport to be predictions of future events or circumstances, and actual results may differ materially from those expressed by forward-looking statements. All forward-looking statements speak only as of the date made, and Aveanna undertakes no obligation to update or revise any forward-looking statements. whether as a result of new information, future events or otherwise, except as required by law.

Industry and Market Data

Unless otherwise indicated, information contained in this presentation concerning our industry, competitive position and the markets in which we operate is based on information from independent industry and research organizations, other third-party sources and management estimates. Aveanna has not independently verified the information and data obtained from third party sources and cannot assure you of such data's accuracy or completeness. Management estimates are derived from publicly available information released by third-party sources, as well as data from our internal research, and are based on assumptions made by us upon reviewing such data, and our experience in, and knowledge of, such industry and markets, which we believe to be reasonable. Any industry forecasts are based on data (including third-party data), models and experience of various professionals and are based on various assumptions, all of which are subject to change without notice. In addition, projections, assumptions and estimates of the future performance of the industry in which we operate, and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described in "Cautionary Note Regarding Forward-Looking Statements." These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

Non-GAAP Financial Measures

This presentation includes various performance indicators and non-GAAP financial measures that we use to help us evaluate our business, identify trends affecting our business, formulate business plans, and make strategic decisions. EBITDA, Adjusted EBITDA, Free Cash Flow, and pro forma presentations of the foregoing are financial measures that are calculated and presented on the basis of methodologies other than in accordance with generally accepted accounting principles in the United States of America ("GAAP"). Reconciliations of such non-GAAP measures to their nearest comparable GAAP measures can be found in the Appendix to this presentation. Any non-GAAP financial measures used in this presentation are in addition to, and not meant to be considered superior to, or a substitute for, the Company's financial statements prepared in accordance with GAAP.

Additional information with respect to Aveanna is contained in its filings with the SEC and is available at the SEC's website, www.sec.gov, and on Aveanna's website, www.aveanna.com

Transforming the Value of Homecare

Aveanna offers a leading, diversified homecare platform that delivers innovative care to pediatric, adult, and geriatric patients. With locations in 33 states, Aveanna has established a national footprint dedicated to high-quality clinical outcomes and enhanced value to our payor and government partners.





Leadership Presenters



Jeff Shaner Chief Executive Officer

- CEO of Aveanna since 2023
- Instrumental in formation of Aveanna Healthcare
- Chief Operating Officer of Aveanna Healthcare since 2017
- Chief Operating Officer of PSA Healthcare since 2015
- Former SVP, President of Operations of Gentiva Health Services
- Former President of Gentiva Health Services' Hospice Division


Matt Buckhalter Chief Financial Officer

- CFO of Aveanna since 2023
- Integral to Aveanna's financial structure since inception
- Senior Vice President of Finance for Aveanna Healthcare since 2016
- Leads the Company's Investor Relations
 Group
- Former Vice President of Finance of PSA Healthcare since 2015

Debbie Stewart Principal Accounting Officer

- Principal Accounting Officer of Aveanna since 2023
- Vice President of Accounting and Controller of Aveanna since 2021
- Leads the Company's Accounting, Tax, SEC Reporting and Internal Audit teams
- Former Assurance Senior Manager of Ernst & Young
- Certified Public Accountant since 2009

Aveanna Overview



due to the volatility of certain required inputs that are not available without unreasonable efforts, including future fair value adjustments associated with our interest rate derivatives, 2, Q3 2024 Gross Margin 3, Q3 YTD 2024 PDS Hours annualized 4, Q3 YTD 2024 Payor mix

Aveanna's Transformative Homecare Platform



Our advanced homecare platform positions us to improve outcomes with data-driven results and introduce value-based agreements that deliver exceptional value to our partners.



୶ୄ

Scaled National Platform

Preferred Payor Partnerships

Government Affairs Strategy


Technology and Data Driven Results

Improved Clinical Outcomes




Aveanna's Transformative Homecare Platform

2023 resulted in substantial progress as demonstrated by key performance metrics.⁽¹⁾



Aveanna's Transformative Homecare Platform

Our future opportunity will continue to provide enhanced value that is driven by our significant investment in our value-based national homecare platform.



Aveanna Business Segments



PRIVATE DUTY SERVICES MEDICAL SOLUTIONS



HOME HEALTH & HOSPICE

Private Duty Services Segment

By The Numbers			
Financial Highlights	Key Operating Statistics		
\$1,617m Net Revenue ¹	228 Locations		
26% – 28% Gross Margin ²	27 States	38,000 Patients on Service	
3% – 5% Organic Growth Rate ³	~47% % of PP Volume	21 Preferred Payors	

Key Items

- Preferred Payor Partnerships underpinned by enhanced rates and value-based agreements
- Defined Government Affairs Strategy in every state
- Scaled National Recruiting Platform to accelerate caregiver hiring
- Technology and Data Driven Outcomes that support value-based agreements
- Strategic M&A tuck in opportunities in key states



- One Nurse One Patient
- Full Time & Per Diem Caregivers Paid by the Hour
- Longer Length of Stay
- Patient Demand Exceeds
 Caregiver Supply
- Services Delivered in the Comfort of the Patient's Home



1. Q3 YTD 2024 Annualized revenue. 2. Management's target for gross margin percentages over time. 3. Management's target for total organic revenue growth rate over time.

Medical Solutions Segment

By The Numbers			
Financial Highlights	Key Operating Statistics		
\$172m Net Revenue ¹	37 States we deliver to		
41% – 44% Gross Margin ²	2-3Years Avg. Case Length	30,000 Patients on Service	
8% – 10% Organic Growth Rate ³	~\$460 Rate / UPS	3 Preferred Payors	



- Preferred Payor Contracts provide in-network patient support at favorable rates
- Enhanced AMS Model driving need to refine our payor network with focus on preferred payors
- Nationally Scaled Enteral Provider
- Strong Patient Demand drives growth trends
- Symbiotic relationship with PDN services



- Nutritional Support Enteral Product, Equipment and Supplies
- Provided to Pediatric, Adult, and Geriatric Patients
- 24-hour Clinical Support
- Longer Length of Stay
- Leading National Enteral
 Provider



^{1.} Q3 YTD 2024 Annualized revenue. 2. Management's target for gross margin percentages over time. 3. Management's target for total organic revenue growth rate over time.

Home Health & Hospice Segment

By The Numbers			
Financial Highlights	Key Operating Statistics		
\$218m	83		
Net Revenue ¹	Locations		
48% – 50%	15	13,500	
Gross Margin ²	States	Patients on Service	
5% – 7%	>70%	38	
Organic Growth Rate ³	Episodic Mix	Preferred Payors	

Key Items

- HH Preferred Payors defined as episodic agreements
- · Caregiver Capacity aligned with preferred payors
- Episodic Payor Agreements and Value-based Payments driven by CMS Star Ratings
- Organic growth initiatives that support the preferred payor strategy



Home Health

- Geriatric Patient Population
- Intermittent Services
- Shorter Length of Stay
- Value-based Care Component
- RN, PT, OT, SLP, SW and HHA


Hospice

- Geriatric Patient Population
- Per Diem Reimbursement
- End-of-life Care / Support




^{1.} Q3 YTD 2024 Annualized revenue. 2. Management's target for gross margin percentages over time. 3. Management's target for total organic revenue growth rate over time.

Scaled Platform Built for Driving Growth and Enhancing Value




Fragmented Home Care Markets Support Sustainable Growth



Q3 2024 Financial Performance: Summary Results

Consolidated Results			
\$ in millions	Q3 2023	Q3 2024	Y/Y% Change
Revenue	\$478.0	\$509.0	6.5%
Gross Margin	\$147.3	\$159.7	8.4%
Adjusted EBITDA ⁽¹⁾	\$36.2	\$47.8	32.2%

Revenue and Gross Margin % by Segment



Key Highlights

- PDS Q3 2024 revenue growth of 6.4% from Q3 2023, driven by 10.5 million hours of care or 3.8% YOY volume increase
- MS Q3 2024 revenue growth of 12.6% from Q3 2023, driven by strong rate improvement of 8.1%
- HHH Q3 2024 gross margin percentage growth of 6.0% from Q3 2023, driven by strong episodic mix and caregiver utilization
- Q3 2024 demonstrated continued focus on optimization across Aveanna's overhead platform and preferred payor strategy
- 2024 Operating Cash Flow of positive \$19.2m and Free Cash Flow of positive \$16.7m⁽²⁾

Financial Performance: Capital Structure

Liquidity

- Liquidity of over \$284.6m, comprised of the following:
 - \$78.5m cash on balance sheet
 - \$168.2m revolver availability
 - \$37.9m securitization availability
- Undrawn revolver at the end of Q3
- \$32m in outstanding letters of credit at the end of Q3

Cash Flow

- FY 2023 free cash flow of \$12.5m⁽¹⁾
- 2024 cash provided by operating activities of \$19.2m
- 2024 free cash flow of \$16.7m⁽¹⁾
- Goal to drive positive operating cash flow FY 2024

Indebtedness and Hedging

- Total variable rate debt of \$1,480m, consisting of:
 - First Lien: \$895m (S + 3.75%)
 - Second Lien: \$415m (S + 7.00%)
 - Securitization: \$170m (S + 3.15%)
- Interest rate hedges in place:
 - \$520m notional interest rate swap (expires June 2026)
 - \$880m notional, 3% interest rate cap (expires February 2027)





Path Forward: Strategic and Operational Focus on Driving Shareholder Value



Core Organic Growth



Value-based Growth



Enhanced Capital Structure



Appendix

Reconciliation of Net Loss to Adjusted EBITDA

	For the three-month periods ended		
(dollars in thousands)	Sept	tember 28, 2024	September 30, 2023
Net loss	\$	(42,843)	\$ (102,389)
Interest expense, net		39,145	39,549
Income tax expense		15,511	631
Depreciation and amortization		2,587	2,962
EBITDA		14,400	(59,247)
Goodwill, intangible and other long-lived asset impairment		2,904	106,841
Non-cash share-based compensation		4,902	5,116
Interest rate derivatives (1)		22,141	(14,120)
Acquisition-related costs (2)		150	428
Integration costs (3)		262	497
Legal costs and settlements associated with acquisition matters (4)		848	346
Restructuring (5)		1,599	985
Other legal matters (6)		214	-
Other system transition costs, professional fees and other (7)		421	(4,655)
Total adjustments (8)	\$	33,441	\$ 95,438
Adjusted EBITDA	\$	47,841	\$ 36,191

Reconciliation of Net Cash (Used in) Provided by Operating Activities to Free Cash Flow

	For the fig	scal year ended
(dollars in thousands)	Decem	nber 30, 2023
Net cash provided by operations		22,672
Purchases of property and equipment, and software		(6,116)
Principal payments of term loans		(9,200)
Principal payments of notes payable and financing lease obligations		(10,483)
Settlements with swap counterparties		15,632
Free cash flow	\$	12,505

	For the nine-month period ended		
(dollars in thousands)	Septem	ber 28, 2024	
Net cash provided by operating activities		19,231	
Purchases of property and equipment, and software		(4,790)	
Principal payments of term loans		(4,600)	
Principal payments of notes payable and financing lease obligations		(4,802)	
Settlements with swap counterparties		11,681	
Free cash flow	\$	16,720	